Fullerene carbon nanotubes as delivery agents for cancer therapeutics

Ensysce Biosciences has developed two innovative technology platforms, TAAP™ (Trypsin-Activated Abuse Protection) and MPAR® (Multi-Pill Abuse Resistance), aimed at addressing the critical issues of prescription drug abuse and overdose. The TAAP™ technology utilizes a unique two-step activation process that ensures opioids are only activated when ingested and come into contact with the digestive enzyme trypsin in the small intestine. This mechanism prevents the manipulation of the drug through methods such as crushing or injecting, thereby significantly reducing the potential for abuse. TAAP™ products, such as PF614, are designed to provide extended pain relief while maintaining a low risk of misuse, as they are chemically stable until properly ingested.

Complementing the TAAP™ platform, the MPAR® technology adds an additional layer of safety by inhibiting the activation of the drug if excessive amounts are consumed. This feature is particularly crucial in preventing accidental or intentional overdoses, as it allows the medication to pass through the body without being activated. Both technologies have received significant recognition, with TAAP™ being granted FDA "Fast Track" designation and MPAR® receiving "Breakthrough Therapy" designation. Ensysce's commitment to innovation in drug delivery and safety positions it as a leader in developing next-generation therapies for pain management and other conditions, while actively contributing to the fight against the opioid crisis.

United States

Ensysce Biosciences, Inc. (NASDAQ: ENSC) is a clinical-stage biotech company developing a new class of prescription drugs that will provide patients and prescribers safer options for the use of potent prescription drugs, reducing abuse and preventing overdoses.

Ensysce Biosciences

Company Details